News

Our News

Device that extracts brain tumors gains FDA breakthrough status

A advice that aims to draw aggressive brain tumor cells to the exterior of the brain...

Cancer: 'Tumour monorail' can lead cancers to their doom

Cancer "monorails" can be used to kill tumours by luring them into toxic pits or areas of the body that are safer to operate on, say US researchers.

Promising brain tumor treatment hijacks "monorail" that lets cancer spread

Breakthrough Status Achieved for IFF-Backed Tumor Monorail Device

A biomedical tool that tricks aggressive brain tumors into moving into an external container instead of throughout the brain has been designated a “breakthrough device” by the FDA.

New ‘gel’ device lures aggressive brain tumour cells out

Reevaluating Biopsy in Recurrent Glioblastoma Christopher Davidson Forum Investigators Position Statement (2021)

Patients with glioblastoma (GBM) need bold new approaches to their treatment, yet progress has been hindered by a relative inability to dynamically track treatment response, mechanisms of resistance, evolution of targetable mutations, and changes in mutational burden.

Correcting the drug development paradigm for glioblastoma requires serial sampling (2023)

A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials

Enroll in the trial

Exvade is conducting a First-in-Human study of the Tumor Monorail Device at the Preston Robert Tisch Brain Tumor Center at Duke University, evaluating its safety and advancing a transformative shift in how cancer is treated.

Enroll in our clinical trial and contribute to the development of innovative solutions that prioritize patient care and outcomes.

Enroll now Learn more

“By allowing real-time monitoring of the tumor over time, while on therapy, we will hopefully be able to more swiftly identify the degree of efficacy or the limitations of our therapies, while preventing the trauma and costs of repeated brain surgery.”

- Dr. Annick Desjardins, MD, FRCPC, neuro-oncologist,
professor of neurosurgery and neurology at Duke University